U.S. Department of Veterans Affairs (VA) Under Secretary of Health, Dr. Shereef Elnahal, spoke with Executive Director of Healing Breakthrough Executive Director, Dr. Jason Pyle, onstage at the Horizons conference in New York

Healing Breakthrough celebrates the FDA’s latest announcement on MDMA-AT, bringing the promising therapy one step closer to healing Veterans who suffer from PTSD.

https://news.va.gov/press-room/to-improve-care-for-veterans-va-to-fund-studies-on-new-therapies-for-treating-mental-health-conditions/

https://news.va.gov/press-room/to-improve-care-for-veterans-va-to-fund-studies-on-new-therapies-for-treating-mental-health-conditions/

At least four times as many active duty personnel and war veterans of post-9/11 conflicts have died of suicide than in combat. Researchers at the VA have found that 17 Veterans a day lose their life to suicide with suicide being the second leading cause of death among Veterans under the age of 45.

At least four times as many active duty personnel and war veterans of post-9/11 conflicts have died of suicide than in combat. Researchers at the VA have found that 17 Veterans a day lose their life to suicide with suicide being the second leading cause of death among Veterans under the age of 45.

In June 2023, the FDA issued its first draft guidance on clinical trials with psychedelic drugs. The 14-page document presents non-binding guidance, or recommendations, regarding study design and other considerations for drug development programs investigating the therapeutic potential of…

In Phase II studies, researchers administer the drug to a group of patients with a disease or condition. A Phase III clinical trial tests the safety and how well a new treatment works compared with a standard treatment.